Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT03838926
Recruiting Phase 1

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

NCT03838926 · tracked via the Priya Life Science USA tracker
Sponsor
Vanda Pharmaceuticals
Phase
Phase 1
Started
2018-09-27
Last updated
2026-03-16

Condition(s) studied

Relapsed or Refractory Hematologic Malignancies

Investigational drug(s) / intervention(s)

Trichostatin A →

Trichostatin A: Intravenous Infusion

Study summary

The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Subject is ≥ 18 years at the time of signing informed consent; * Confirmed malignant hematologic disease or lymphoid malignancy that has relapsed or is refractory to standard therapy and has exhausted all available therapies; * Presence of measurable or evaluable disease; * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2; * Contraceptives or other approved avoidance of pregnancy measures Exclusion Criteria: * Allogeneic stem cell transplant recipient presenting with graft versus host disease (GVHD) either active or requiring immunosuppression; * Concomitantly taking anti-cancer therapy (bisphosphonates are permitted); * Undergone major surgery ≤ 2 weeks prior to starting study drug; * Evidence of mucosal or internal bleeding; * Impaired cardiac function or conduction defect; * Concurrent severe and/or uncontrolled medical conditions

Primary outcome measure(s)

  • Safety and tolerability of trichostatin A measured by spontaneous reporting of adverse events (AEs) — Up to 24 months
    Measured by spontaneous reporting of adverse events (AEs)
  • Dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of trichostatin A — Up to 24 months

Trial sites (11)

FacilityCityRegionStatus
Vanda Investigational Site Washington D.C. District of Columbia Withdrawn
Vanda Investigational Site Lafayette Indiana Completed
Vanda Investigational Site Hackensack New Jersey Withdrawn
Vanda Investigational Site Seattle Washington Completed
Vanda Investigational Site Biała Podlaska Poland Recruiting
Vanda Investigational Site Katowice Poland Recruiting
Vanda Investigational Site Krakow Poland Completed
Vanda Investigational Site Opole Poland Recruiting
Vanda Investigational Site Skorzewo Poland Completed
Vanda Investigational Site Warsaw Poland Recruiting
Vanda Investigational Site Wroclaw Poland Completed

More Vanda Pharmaceuticals trials in the USA

Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances Recruiting
Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis Recruiting
ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection Enrolling by invitation
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension Recruiting
Patient Registry of Blind Subjects With Sleep-related Problems Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03838926 on ClinicalTrials.gov ↗ ← All trials in the USA